Ondansetrón Teva-Ratio (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón Teva-Ratio, is a serotonin 5-HT3 receptor antagonist presented as a 4 mg oral tablet for oral use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetrón Teva-Ratio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is employed across several clinical pathways that involve emesis control.

- Chemotherapy‑induced nausea and vomiting (CINV): reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting (RINV): helps maintain patient comfort during and after radiation treatment. - Post‑operative nausea and vomiting (PONV): lowers the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑associated nausea (hyperemesis gravidarum): provides relief when other measures are insufficient.

Side‑effect profiles reflect the drug’s pharmacology and patient variability.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: general tiredness. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - QT‑interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant‑like reactions: extremely uncommon but serious.

When prescribing Ondansetron, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known QT prolongation. - Electrolyte balance: correct hypokalaemia, hypomagnesaemia or hypocalcaemia before use. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome. - Pregnancy: weigh benefits against potential risks; use only if clearly needed. - Renal/hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): potential for serotonin syndrome. - Tramadol and other opioids: heightened serotonergic activity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): altered metabolism may occur.